The handle http://hdl.handle.net/1887/25869 holds various files of this Leiden University dissertation

**Author:** Wout, Emily F.A. van ‘t

**Title:** Endoplasmic reticulum stress in the lung : lessons from α1-antitrypsin deficiency

**Issue Date:** 2014-06-04
Chapter 5

Increased ERK signalling promotes inflammatory signalling in primary airway epithelial cells expressing Z α₁-antitrypsin

Emily F.A. van ‘t Wout¹², Jennifer A. Dickens¹, Annemarie van Schadewijk², Imran Haq¹, Hang Fai Kwok³, Adriana Ordóñez¹, Gillian Murphy³, Jan Stolk², David A. Lomas¹⁴, Pieter S. Hiemstra””, Stefan J. Marciniak””

¹ Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/Medical Research Council Building, Cambridge, United Kingdom
² Department of Pulmonology, Leiden University Medical Centre, Leiden, the Netherlands
³ Department of Oncology, University of Cambridge, Proteases and Tumour Microenvironment Group, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
⁴ Wolfson Institute for Biomedical Research, University College London, London, United Kingdom
” Joint senior authors

Human Molecular Genetics 2014; 23:929-941
Abstract

Overexpression of Z α₁-antitrypsin is known to induce polymer formation, prime the cells for ER stress and initiate NF-κB signalling. However, whether endogenous expression in primary bronchial epithelial cells has similar consequences remains unclear. Moreover, the mechanism of NF-κB activation has not yet been elucidated. Here we report excessive NF-κB signalling in resting primary bronchial epithelial cells from ZZ patients compared to wild-type (MM) controls, and this appears to be mediated by MEK, EGFR and ADAM17 activity. Moreover, we show that rather than being a response to protein polymers, NF-κB signalling in airway-derived cells represents a loss of anti-inflammatory signalling by M α₁-antitrypsin. Treatment of ZZ primary bronchial epithelial cells with purified plasma M α₁-antitrypsin attenuates this inflammatory response, opening up new therapeutic options to modulate airway inflammation in the lung.
Introduction

Alpha₁-antitrypsin is a 52-kDa serine protease inhibitor (or serpin), primarily produced by hepatocytes, but also secreted locally by lung epithelial cells and alveolar macrophages (1, 2). Its known function is to inhibit a number of serine proteases, including neutrophil elastase and proteinase 3, thereby preventing excessive degradation of the extracellular matrix. It has also been reported to exhibit anti-inflammatory properties, including the inhibition of TNFα gene expression (3), inhibition of a disintegrin and metalloprotease (ADAM)17 activity in neutrophils and endothelial cells (4, 5) and the regulation of CD14 expression and cytokine release in monocytes (6, 7).

The Z mutation (E342K) of α₁-antitrypsin causes subtle misfolding of the protein that permits polymer formation and accumulation within the endoplasmic reticulum (ER) of hepatocytes or degradation by the proteasome leading to deficiency of the secreted protein (8, 9). This causes hepatic cirrhosis through toxic gain-of-function within the liver, most likely due to the retention of polymers, and early-onset lung emphysema, due in large part to the loss of protease inhibition (10). The discovery of polymers in bronchoalveolar lavage fluid and pulmonary tissue (11, 12), the pro-inflammatory nature of such extracellular polymers (11, 13) and their identification many years after liver transplantation (14) led to the proposal that pulmonary pathology could be induced by polymer-induced toxic gain-of-function with inflammation as an additional mechanism (15).

Secreted proteins are first folded within the ER where quality control systems ensure that only properly folded proteins exit the organelle (16). Accumulation of unfolded or misfolded proteins within the ER induces “ER stress”, thereby activating intracellular signal transduction pathways, collectively called the unfolded protein response (UPR) (16). This complex cellular response evolved to restore ER homeostasis by reducing the load of newly synthesised protein while increasing the complement of molecular chaperones, which enhance ER protein folding capacity, and increasing the efficiency of misfolded protein degradation (ERAD) (17, 18). We have shown previously that mutant Z α₁-antitrypsin is degraded predominantly by ERAD (19). Remarkably, the accumulation of polymers of Z α₁-antitrypsin within the ER of hepatocytes does not activate the UPR but
instead increases the cell’s sensitivity to ER-stress upon a ‘second hit’ due to impaired ER luminal protein mobility (20-22).

The transcription factor nuclear factor kappa B (NF-κB) regulates many genes involved in inflammation and cell death, including numerous cytokines and chemokines e.g. interleukin (IL)-8 (23). Phosphorylation of NF-κB is classically mediated through the phosphorylation of inhibitor kappa-B alpha (IκBα); however, NF-κB can also be activated via mitogen-activated protein kinase (MAPK) signalling cascades (24, 25).

Epidermal growth factor (EGF) and related mitogens such as heparin binding-EGF (HB-EGF), amphiregulin (AREG) and transforming growth factor (TGF)α are synthesised as membrane-bound proteins that upon cleavage by metalloproteases (MPs), including ADAMs, bind to and activate the EGF receptor (EGFR) (reviewed in (26)). Transactivation of the EGFR can also occur via activation of ADAMs by G-protein coupled receptor signalling (reviewed in (27)). Within the lung, EGFR activation can induce epithelial cell proliferation by activating ERK1/2. This is mediated by Ras activation of c-Raf, causing phosphorylation of the mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK), which in turn phosphorylates ERK1/2 (28).

Mutants of members of the serpin superfamily, including α1-antitrypsin, have been shown to activate NF-κB signalling, postulated to be a response to the formation of protein polymers within the ER (20, 21, 29). However, this appears to be independent of their ability to prime cells for ER stress (29). Whether the local expression of Z α1-antitrypsin by airway epithelial cells in vivo leads to the formation of protein polymers and to the activation of the NF-κB pathway remains unclear. We report here the detection of NF-κB activation in primary bronchial epithelial cells isolated from patients homozygous for the Z mutation (ZZ) and demonstrate this to be mediated by increased ADAM17-dependent EGFR-MEK-ERK signalling in the absence of either detectable polymer formation or ER stress response. Instead, the activation of the EGFR in this setting represents a loss of M α1-antitrypsin phenotype.
Results

Z α1-antitrypsin activates NF-κB in lung epithelial cells

It is well-recognised that overexpression of Z α1-antitrypsin activates the NF-κB response leading to pro-inflammatory cytokine release (20, 21, 30). We therefore asked whether expression of Z α1-antitrypsin regulated by its endogenous promoter in airway epithelial cells could also activate this pathway. Primary bronchial epithelial cells were differentiated into mucin producing, ciliated epithelial cell layers (Figure 1A) and a multiplex ELISA (Meso Scale Discovery®) of apical washings (air exposed) and basal (liquid exposed) conditioned medium for IL-8, IL-6, TNFα, IL-1β, MCP-1 and IP-10 was performed (Figure 1B). This revealed that resting ZZ differentiated primary bronchial epithelial cells secreted more IL-8 basally when compared to MM cells (p<0.01). After combined stimulation with oncostatin M (OSM), TNFα and IL-1β (OSM-mix), ZZ differentiated primary bronchial epithelial cells showed significantly higher release of MCP-1 (p<0.01), IP-10 (p<0.05) and IL-1β (p<0.01) compared to MM controls. The reduced secretion of IL-8 most likely reflects the known inhibitory effect of OSM on IL-1β-induced IL-8 release (31). To determine whether this enhanced release of cytokines was mediated by increased NF-κB signalling, submerged cultures of patient-derived ZZ primary bronchial epithelial cells were induced to express increased levels of α1-antitrypsin by treatment with OSM and NF-κB activity was assayed using a luciferase reporter system (Figure 1C) (29). Low levels of basal NF-κB luciferase activity were detected in MM primary bronchial epithelial cells, whereas ZZ cells showed significantly higher activity at baseline (p<0.05 compared to MM; Figure 1C). When α1-antitrypsin production was increased by treatment with OSM, the NF-κB activity in ZZ primary bronchial epithelial cells increased significantly (p<0.001) and the difference between MM and ZZ cells further increased (p<0.01). Stimulation with TNFα, a cytokine known to induce NF-κB activation, showed the same difference between MM and ZZ cells (p<0.05). The same effect was seen in Tet-On A549 cells overexpressing either M or Z α1-antitrypsin (Figure S1). To test if the baseline difference in NF-κB activity was related to the transfection of the reporter constructs, we measured transcription
A. Submerged until confluent

B. ELISA analysis of cytokines.

C. NF-κB luciferase activity.

D. IL-8 mRNA expression.

**p<0.01
***p<0.001
*p<0.05

**p<0.01
***p<0.001
*p<0.05
of the NF-κB-dependent chemokine IL-8, which confirmed basal levels of inflammatory signalling were higher in ZZ primary bronchial epithelial cells compared with controls (p<0.05; Figure 1D).

**Z α1-antitrypsin does not form detectable polymers nor causes ER stress in lung epithelial cells**

NF-κB activation by mutant serpins has previously been associated with the accumulation of protein polymers within the ER (20-22, 29). This accumulation has also been shown to exaggerate ER stress upon a second hit (20, 22). To verify whether this mechanism was responsible for the enhanced NF-κB signalling in fully differentiated ZZ primary bronchial epithelial cells, we first measured total secreted and intracellular α1-antitrypsin. Resting primary bronchial epithelial cells produced unquantifiable amounts of α1-antitrypsin, but after stimulation with OSM-mix for 48 hours, α1-antitrypsin was detectable in both the apical washes and basal supernatant (Figure 2A). Similar results were obtained after exclusion of the current smokers, indicating that the differences
in smoking status of the patients between MM and ZZ patients from which cells were
obtained did not explain the differences in production of α₁-antitrypsin (data not
shown). Using the 2C1 monoclonal antibody that specifically detects naturally occurring
polymers of Z α₁-antitrypsin (32), we found no evidence of polymer formation (Figure 2A).
Accordingly, we could detect no differences in ER protein mobility (Figure S2), which we
have previously shown occurs in cells containing ER luminal polymers of α₁-antitrypsin
(22). To determine if the absence of polymer formation was a feature of lung epithelial
cells, we generated stable transfected A549 lung carcinoma cell lines that conditionally
expressed either M or Z α₁-antitrypsin under the control of a Tet-On responsive promoter.
As expected, M α₁-antitrypsin-expressing A549 cells secreted five-times more α₁-
antitrypsin than did Z α₁-antitrypsin-expressing A549 cells (Figure 2B). Again, we were
unable to detect protein polymers in either the supernatant or cellular lysates (Figure
2B). Since polymer formation is dependent upon α₁-antitrypsin concentration (8), we

Figure 2. Polymer formation and an (exaggerated) ER stress response are not causing the
augmented NF-κB response.

A. Total α₁-antitrypsin (AAT) and α₁-antitrypsin polymer production of fully differentiated primary bronchial
epithelial cells stimulated with OSM mix for 48 hours. Note lack of polymer signal with the 2C1 antibody
(mean, n=6). B. Total α₁-antitrypsin and α₁-antitrypsin polymer production of the overexpressing Tet-On
A549 cells after inducing for 48 hours with doxycycline (dox; mean ± SEM, n=3). C. Total α₁-antitrypsin
levels produced by ZZ lung epithelial cells compared to ZZ liver homogenate (n=3 from one individual).
D. Quantitative RT-PCR of fully differentiated primary bronchial epithelial cells treated ± OSM mix for 48
hours. Four hours before harvesting, cells were stimulated with tunicamycin (Tm; 1 µg/ml). Spliced XBPI,
CHOP and GADD34 mRNA levels are displayed normalised to the housekeeping genes RPL13A and ATP5B
(mean, n=6). E. Western blot for GRP94 and GRP78 using anti-KDEL antibody. Cells were treated as in
D, but stimulated for 16 hours with tunicamycin (mean, n=6). N.D. not detectable. *p<0.05, **p<0.01,
***p<0.001 versus – or 0 with a two-way repeated-measurements ANOVA (Bonferroni post-hoc).
The ERK pathway in α1-antitrypsin deficiency

- **A**
  - Bar graph showing AAT (ng/mg total lysate) expression in apical and basal lysates with OSM mix induction. Statistical significance indicated by *p* < 0.01 and *p* < 0.05.

- **B**
  - Bar graph showing AAT (mg/ml) expression in lysate and supernatant with dox (µg/ml) treatment. STMs for MM A549.

- **C**
  - Bar graph showing AAT (ng/mg total lysate) expression in total and polymers for PBBEC, A549, and liver.

- **D**
  - Graphs showing spliced XBP1 mRNA (normalized expression) and GAPDH mRNA (normalized expression) with dox (µg/ml) treatment.

- **E**
  - Western blot analysis showing GRP94, GRP78, and GAPDH protein levels with OSM mix treatment.
compared the relative levels of α₁-antitrypsin in tissue from an explanted cirrhotic ZZ liver (Figure 2C) with those in cultured airway epithelial cells. This revealed a 100-fold higher level of α₁-antitrypsin in hepatic tissue and significant polymer accumulation (Figure 2C). While polymerisation of α₁-antitrypsin in vitro is highly dependent upon protein concentration, the concentration-dependence of polymerisation within the crowded environment of the endoplasmic reticulum in vivo is not known. Therefore, to determine the critical concentration for the polymerisation of Z α₁-antitrypsin in living cells, we induced the expression of Z α₁-antitrypsin in Tet-On stable CHO stable cells (22) and measured both total α₁-antitrypsin and polymer levels (Figure S3A). This revealed that levels of 300 ng α₁-antitrypsin per mg total lysate protein are necessary before intracellular polymers can be detected in these cells (Figure S3A). To test this finding in lung epithelial-derived cells, we induced expression of Z α₁-antitrypsin in Tet-On A549 cells with doxycycline and augmented the protein level by inhibiting endoplasmic reticulum associated degradation (ERAD) with lactacystin, a selective proteasome inhibitor. This increased the concentration of intracellular Z α₁-antitrypsin above 300 ng α₁-antitrypsin per mg total lysate, whereupon polymers were detected (Figure S3B). It therefore seems likely that the low levels of α₁-antitrypsin produced by airway epithelia are insufficient to generate detectable polymers.

To define whether Z α₁-antitrypsin expressed in epithelial cells alters the ER stress response, we induced expression of α₁-antitrypsin in fully differentiated primary bronchial epithelial cells with OSM-mix in the presence or absence of the ER stress-inducing toxin tunicamycin. We detected no differences in the basal or OSM-mix-stimulated levels of spliced XBP1, CHOP, and GADD34 mRNA between MM and ZZ primary bronchial epithelial cells (Figure 2D). As expected, tunicamycin increased the level of these transcripts; however, there was not an exaggerated ER stress response in ZZ epithelial cells (Figure 2D). Similarly, we were unable to detect differences in ER stress by western blot for the KDEL-positive chaperones, GRP94 and GRP78, in ZZ and MM cells (Figure 2E).
Figure 3. Increased NF-κB response in ZZ primary bronchial epithelial cells is dependent on the ERK/MEK/EGFR pathway.

A. Representative western blot of the activation of the MAP kinases ERK1/2, JNK and p38 MAPK of whole cell lysates from undifferentiated primary bronchial epithelial cells knocked-out for α₁-antitrypsin (AAT) with siRNA. Cells were cultured overnight, transfected for 24 hours and left 48 hours before harvesting. Neuroserpin (NS) siRNA served as a control. Densitometry of four independent experiments in duplicate (mean, n=4). B. ZZ primary bronchial epithelial cells treated for 24 hours with 1 mg/ml purified plasma M α₁-antitrypsin normalised ERK1/2 levels. Densitometry of four independent experiments in duplicate (mean, n=4). C. ZZ primary bronchial epithelial cells treated with 10 µM U0126 (a specific MEK inhibitor) for 8 hours or 2 µg/ml anti-EGFR blocking antibody for 24 hours. Densitometry of three independent experiments in duplicate (mean, n=3). *p<0.05, **p<0.01, ***p<0.001 versus – or 0 with a two-way repeated-measurements ANOVA (Bonferroni post-hoc).
Loss of M α₁-antitrypsin leads to increased activation of ERK, which is dependent on MEK and EGFR

In order to understand the mechanism of inflammatory signalling in ZZ epithelial cells, we next evaluated activation of the NF-κB pathway components IKKβ, IκBα and p65. To evaluate MAPK signalling, we also measured JNK, p38 MAPK and ERK1/2. This revealed a significant difference only in the activation of ERK (p<0.05; Figure 3A and S4). Interestingly, depletion of α₁-antitrypsin by siRNA caused phosphorylation of ERK1/2 in MM primary bronchial epithelial cells, but did not alter the phosphorylation of ERK1/2 in ZZ cells (Figure 3A). This effect was specific for ablation of α₁-antitrypsin, since silencing a nonspecific serpin, neuroserpin (NS), did not increase phosphorylation of ERK1/2 in MM cells. This suggested that it was the lack of M α₁-antitrypsin, rather than the presence of Z α₁-antitrypsin, that might be responsible for the phosphorylation of ERK1/2 in ZZ primary bronchial epithelial cells. To test this, we treated ZZ primary bronchial epithelial cells with plasma purified M α₁-antitrypsin and observed a suppression of ERK1/2 phosphorylation (p<0.05; Figure 3B). We wished to determine whether this loss of function phenotype reflected a lack of anti-inflammatory activity in Z α₁-antitrypsin or if cells secreted insufficient Z α₁-antitrypsin. Since concentration of plasma purified Z α₁-antitrypsin to a degree required for this experiment would result in its polymerisation, we instead transiently transfected HeLa cells with either M or Z α₁-antitrypsin or empty vector as control. After transfection, the cells produced high levels of α₁-antitrypsin, with ZZ cells producing approximately 20% of the amount that MM cells produced (444 ng/mg α₁-antitrypsin in the total lysate versus 1995 ng/mg α₁-antitrypsin in the total lysate respectively; Figure S5A). Although 14% (33 ng/mg total lysate) of the extracellular Z α₁-antitrypsin formed polymers (not shown), the protein was able to inhibit phosphorylation of ERK1/2 to a similar degree as M α₁-antitrypsin (Figure S5B). This result is consistent with a model in which ZZ primary bronchial epithelial cells secrete insufficient α₁-antitrypsin to inhibit ERK1/2 phosphorylation, rather than Z α₁-antitrypsin lacking the anti-inflammatory activity per se.

To determine the mechanism of ERK1/2 phosphorylation in ZZ primary bronchial
epithelial cells, we treated cells with U0126, a specific inhibitor of MEK, or an anti-EGFR blocking monoclonal antibody. Both reagents abrogated the phosphorylation of ERK indicating that the EGFR-MEK signalling pathway was involved and was activated by the ligand-binding site of EGFR (Figure 3C). Although under some circumstances the activation of ERK1/2 can lead to epithelial cell proliferation, we did not observe differences in the rate of MM and ZZ cell proliferation (Figure S6A). Attempts to assess the effect of ERK1/2 inhibition in each cell type were hampered by toxicity, but it did not appear that modulation of ERK1/2 activation affected proliferation of MM or ZZ cells differentially. Treatment of ZZ cells with purified M α1-antitrypsin did not appear to affect the rate of proliferation (Figure S6B).

ZZ primary bronchial epithelial cells generate higher levels of ADAM17-dependent EGFR ligands

We reasoned that this increased EGFR signalling might reflect increased cleavage of membrane-tethered ligands by MMPs and/or ADAMs. Therefore, we incubated MM and ZZ primary bronchial epithelial cells with GM6001, a broad-spectrum MP-inhibitor, or TAPI-2, a broad-spectrum MP inhibitor with enhanced ADAM17 inhibitory activity. TAPI-2 completely blocked the phosphorylation of ERK1/2 in ZZ cells (p<0.001), while GM6001 failed to affect phosphorylation (Figure 4A). Furthermore, only treatment with TAPI-2 reduced secretion of IL-8 from ZZ cells (p<0.01) (Figure 4B). Since this suggested the involvement of ADAM17, we next tested the effect of a specific ADAM17 blocking antibody, D1(A12) (33). At 200 nM, a concentration known to block the activity of ADAM17 (34), we observed a substantial decrease in phosphorylation of ERK1/2 (p<0.05; Figure 4C).

A previous report suggested that M α1-antitrypsin can directly inhibit ADAM17 derived from neutrophils (4), and so we attempted to reproduce this observation. We first performed an in vitro ADAM17 activity assay by incubating 1 nM ADAM17 with 0-30 µM purified plasma M α1-antitrypsin, but were unable to detect any inhibition of ADAM17 (Figure 4D). When using 10 µM β-mercaptoethanol in PBS or PBS alone, two potent
Chapter 5

A

- GM6001 TAPI-2

| kDa | M | Z | M | Z | M | Z |
|-----|---|---|---|---|---|---|
| 44  | p-ERK 1/2 | p-ERK 1/2 |
| 42  | total ERK 1/2 | total ERK 1/2 |

B

I L-8 (pg/mg total lysate)

- GM6001 TAPI-2

C

- 200 nM D1(A12)

| kDa | M | Z | M | Z |
|-----|---|---|---|---|
| 44  | p-ERK 1/2 | p-ERK 1/2 |
| 42  | total ERK 1/2 | total ERK 1/2 |

D

AFU

- 30 μM MAAT
- 7.5 μM MAAT
- 10 μM β-ME in PBS
- PBS

E

AAT ADAM17

AAT- ADAM17
ADAM17 inhibitors, we were able to inhibit its activity, confirming the functionality of our assay (Figure 4D). Moreover, we were unable to detect the formation of a complex between ADAM17 and either form of α₁-antitrypsin (Figure 4E). Although it remains controversial as to whether cytoplasmic phosphorylation of ADAM17 plays an important regulatory role (35), we also tested for phosphorylation of ADAM17 in MM and ZZ cells grown with or without supplementary M α₁-antitrypsin (Figure S7). We detected no differences between these conditions.

To explore this pathway further, we next measured whether ZZ primary bronchial epithelial cells generated more EGFR ligands than controls. We detected significantly higher levels of mRNA encoding HB-EGF and TGFα in ZZ cells compared with MM controls (p<0.05 and p=0.05; Figure 5A). When the EGFR was blocked using a monoclonal antibody to prevent ligand binding to its receptor, significantly more release of TGFα and AREG was
Figure 5. EGFR ligands are enriched in ZZ primary bronchial epithelial cells.

A. Basal expression levels of the EGFR ligands HB-EGF, TGFα and amphiregulin (AREG) in undifferentiated primary bronchial epithelial cells, measured by qPCR. EGF was not quantifiable (mean, n=4). B. Increased TGFα and AREG in the cell supernatant of ZZ primary bronchial epithelial cells after blockade of the EGFR, quantified by ELISA. HB-EGF was undetectable (mean, n=3). C. Conditioned medium from ZZ primary bronchial epithelial cell culture given to MM primary bronchial epithelial cells and vice versa. Phosphorylation of ERK1/2 was measured 1 and 24 hours after media exchange. Densitometry of four independent experiments in duplicate (mean, n=4). *p<0.05, **p<0.01, ***p<0.001 versus – with a two-way repeated-measurements ANOVA (Bonferroni post-hoc).
The ERK pathway in α₁-antitrypsin deficiency

detected in ZZ cells compared with MM cells (p<0.05; Figure 5B). Consistent with these observations, when we treated MM primary bronchial epithelial cells with conditioned medium derived from ZZ cultures, we observed a significant increase in phosphorylation of ERK1/2 after 1 hour (p<0.01), which returned to baseline after 24 hours (p<0.001; Figure 5C).

Taken together, these data indicate that the increased NF-κB signalling in ZZ primary bronchial epithelial cells is caused by phosphorylation of ERK1/2. This is due

Figure 6. ZZ primary bronchial epithelial cells show an enhanced inflammatory response dependent of the ERK/EGFR/ADAM17 pathway.

Impaired expression of α₁-antitrypsin in primary bronchial epithelial cells leads to increased phosphorylation of ERK1/2, which is dependent on MEK, EGFR and ADAM17. M α₁-antitrypsin modulates this inflammatory response via a yet undefined mechanism.
to increased availability of ADAM17-dependent EGFR ligands leading to activation of the EGFR and signalling via MEK (Figure 6). Surprisingly, we were unable to detect the formation of polymers of α1-antitrypsin in ZZ primary bronchial epithelial cells or A549 lung adenocarcinoma cells overexpressing the protein, which may reflect the low levels of α1-antitrypsin expression of which these cells are capable.
Discussion

For many years, it was thought that an imbalance between protease and antiprotease activity was solely responsible for the accelerated onset of emphysema in patients homozygous for the Z allele of α₁-antitrypsin (reviewed in (36)). However, α₁-antitrypsin has been found to possess additional roles to its antiprotease activity, including a range of anti-inflammatory properties (3-5), and the Z alleles can increase inflammatory NF-κB signalling when overexpressed pulmonary epithelial cells (20, 21, 30). The results of our current study using primary bronchial epithelial cells in which α₁-antitrypsin is expressed under the control of its endogenous promoter, confirm and extend these findings. We found that at the low levels of α₁-antitrypsin expression that occur in these cells, clinically relevant polymer formation is unlikely to occur. Sufficient α₁-antitrypsin is generated by wild-type cells to suppress ERK1/2 and NF-κB signalling, but this anti-inflammatory effect appears to be lost in ZZ epithelia, suggesting a novel mechanism for airway pathology in α₁-antitrypsin deficiency. Surprisingly, while ADAM17 is required to generate secreted EGFR ligands mediating inflammatory signals in these ZZ cells, we were unable to detect a direct inhibition of ADAM17 by M α₁-antitrypsin.

Many heterologous overexpression systems have reported the presence of Z α₁-antitrypsin polymers both intracellular and in conditioned medium (20, 21). Unexpectedly, but importantly, we were unable to detect 2C1-positive polymers in primary bronchial epithelial cultures. Although the 2C1 monoclonal antibody is highly specific for polymers, it is formally possible that it is less sensitive than other anti-polymer antibodies, for example ATZ11. However, in our hands both have similar avidity towards Z polymers, but the polyclonal antibody ATZ11 is less specific for polymers, detecting both Z monomers as well as Z polymers (32). Even if very low levels of Z α₁-antitrypsin polymer is made within bronchial epithelial cells, it is unlikely to affect cellular function as we were unable to detect impaired ER protein mobility nor altered ER stress responsiveness as we have done previously for polymer-expressing cells (22).

We were unable to identify all components required for ERK1/2 activation in ZZ primary bronchial epithelial cells. It is likely that there exists a significant level of
redundancy in this system as we were able to detect multiple EGFR ligands to be increased in the conditioned medium of ZZ cultures. In our system, α₁-antitrypsin did not directly inhibit ADAM17 as has been reported for neutrophils (4). Interestingly, it has recently been speculated that endocytosed α₁-antitrypsin may modulate ADAM17 in endothelial cells (5). If intracellular α₁-antitrypsin can indeed modulate these pathways, multiple potential mechanisms may explain this effect. ADAM-dependent transactivation of the EGFR by activation of G-protein coupled receptors can also occur (reviewed in (27)). For example, IL-8 can induce EGFR phosphorylation in epithelial cells via its receptors CXCR1 and CXCR2 (28, 37), while binding of α₁-antitrypsin to IL-8 has been reported to prevent activation of CXCR1 (4). Although there are contradictory reports concerning the expression of CXCR1 and CXCR2 on bronchial epithelial cells (38, 39), we found that IL-8 release is increased in ZZ primary bronchial epithelial cells, which potentially might provide an autocrine inflammatory signal in the absence of sufficient α₁-antitrypsin. Alternatively, CCL20 (also known as MIP-3α) and its receptor CCR6 have been shown to activate ADAM17 causing transactivation of EGFR (40, 41).

Taken together, our experiments have demonstrated that airway epithelial cells have anti-inflammatory activity due to the local synthesis of M α₁-antitrypsin from its endogenous promoter and that this effect is lacking in ZZ homozygous epithelial cells because of a lack of α₁-antitrypsin secretion. This raises the possibility that α₁-antitrypsin augmentation may have unanticipated effects within the airway. It also raises the potential that targeted anti-EGFR therapy might have anti-inflammatory effects within the lung.
Materials and methods

Reagents and antibodies

OSM (100 ng/ml) was purchased from R&D systems (R&D systems, Minneapolis, MN, USA), and TNFα and IL-1β (both 10 ng/ml) from Peprotech (Peprotech, Rocky Hill, NJ, USA). Tunicamycin (1 µg/ml) was bought from Sigma (Sigma-Aldrich, St.Louis, MO, USA), U0126 (10 nM) from Promega (Promega, Madison, WI, USA), monoclonal (Ab-3) anti-EGFR antibody (2 µg/ml), GM6001 (25 µM) and TAPI-2 (25 µM) all from Calbiochem (Calbiochem, Darmstadt, Germany) and D1(A12) (200 nM) (33). Purified plasma M α1-antitrypsin (1 mg/ml) was derived as described previously (42). All antibodies for immunoblotting were from Cell Signaling (Cell Signaling Technology, Danvers, MA, USA), except secondary HRP-labeled antibodies (Sigma) and GRP94 and GRP78 was detected using an anti-KDEL monoclonal antibody (StressGen).

Cell cultures

Primary bronchial epithelial cells were cultured submerged in a 1:1 mixture of Dulbecco’s modified Eagle’s medium (DMEM) and bronchial epithelial growth medium (BEGM; Clonetics, San Diego, CA, USA) with BEGM SingleQuot supplements and growth factors (Clonetics), 1.5 µg/ml bovine serum albumin (BSA; Sigma-Aldrich), 1 mM HEPES (Invitrogen, Life Technologies, Breda, the Netherlands) and 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma), shortened as full medium, at 37°C, 5% CO₂ (43). Starvation medium consist of full medium except BSA and the SingleQuot supplements EGF and BPE.

We carried out siRNA-mediated knockdown of α1-antitrypsin using a SMARTpool of ONTARGETplus α1-antitrypsin siRNA (Dharmacon, Lafayette, CO, USA) or SERPIN1 siRNA (Dharmacon) as a mock control. In general, 10 nM siRNA and 1 µl RNAiMAX (Invitrogen) was used according to manufacturer’s descriptions and α1-antitrypsin expression, measured with qPCR and ELISA, was knocked down >90% after 72 hours by this method (Figure S8).
Primary bronchial epithelial cells were differentiated as described previously (44). Briefly, cells were cultured submerged until confluence on semi-permeable Transwell membranes (Corning Costar, Cambridge, MA, USA) in B/D medium with addition of retinoic acid (end-concentration 15 ng/ml; Sigma), and subsequently cultured air-exposed for 14 days to allow mucociliary differentiation.

A549 cells were obtained from American Type Culture Collection (ATCC) and stably transfected with the pTetON vector (Clontech) to obtain Tet-On A549 cells. ELISA confirmed that production of endogenous α1-antitrypsin protein was below the level of detection in these cells (data not shown). These were stably transfected with pTRE2-hyg plasmid encoding M or Z α1-antitrypsin as described previously (42). Cells were maintained in DMEM with 10% (v/v) Tetracycline-free Fetal Bovine Serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 400 µg/ml geneticin and 400 µg/ml hygromycin B (selective antibiotics from Invitrogen) at 37°C, 5% CO2. Expression of α1-antitrypsin was usually induced using 2 µg/ml doxycycline (Sigma) for 48 hours. HeLa cells were obtained from ATCC and transient transfected with pcDNA3.1 encoding M or Z α1-antitrypsin (or empty vector) as shown previously (19).

Patient groups

PiZZ α1-antitrypsin deficient patients were recruited in the Leiden University Medical Center (LUMC; Leiden, the Netherlands). ZZ primary bronchial epithelial cells were acquired by bronchial biopsy, with approval from the Medical Ethical Committee of the LUMC. Briefly, bronchial biopsies were washed with PBS, divided in 2mm pieces and placed into a fibronectin/collagen-coated 24-well plate. Twice daily, the explants were fed with 20 µl B/D medium until they became adherent (maximum of three days). Then, primary bronchial epithelial cells were expanded submerged with 500 µl B/D medium, replaced triweekly. When confluent, cells were frozen down in liquid nitrogen until further use. MM primary bronchial epithelial cells were obtained from tumour-free resected lung tissue as described previously (43) and matched to ZZ primary bronchial epithelial cells according to sex, GOLD-stage (0-III) and smoking status (non-, ex-, or current smoker).
• The ERK pathway in α1-antitrypsin deficiency

(Table S1). In each case, care was taken to ensure that cells were sourced only from the 2nd-3rd branches of the bronchial tree in order that results from each were directly comparable.

**Measurement of total α1-antitrypsin, polymerised α1-antitrypsin and cytokine release**

Total and polymerised α1-antitrypsin were measured in whole cell lysate (intracellular) and supernatant (secreted) by ELISA as described previously (32). Cytokine release of fully differentiated cells was measured using a 4-plex Meso Scale Discovery (MSD) kit (IL-6, IL-8, TNFα and IL-1β) and singleplex kits (MCP-1 and IP-10; Meso Scale Discovery, Rockville, MD, USA). EGFR-ligands were measured using commercial available ELISA’s following manufacturer’s protocol (R&D systems). IL-8 release in supernatant of submerged primary bronchial epithelial cultures was quantified using an IL-8 ELISA kit (Sanquin, Amsterdam, the Netherlands).

**Protein mobility assay**

Submerged cultured primary bronchial epithelial cells were grown overnight on coated 35mm glass bottom petri dishes (MatTek Corporation, Ashland, MA, USA) and transiently transfected with an ER-GFP plasmid (45). Live cells were imaged on an LSM510 confocal microscope (DuoScan; Carl Zeiss Inc., Thornwood, NY, USA) at 37°C as defined in (22). Briefly, ER-GFP was visualised with a x63/1.4NA oil objective at 488nm laser and fluorescence recovery after photobleaching (FRAP) experiments were performed. Fluorescence recovery curves were obtained by transforming fluorescence intensities into a percentage scale in which the pre-bleach time point represents 100% of fluorescence intensity.

**Luciferase activity assays**

Transfection with luciferase-reporter plasmids was typically performed in 6-well plates with 1 µg of either p(5x)ATF6-luc (Firefly) or pELAM1-luc (Firefly) and 50 ng of pRL-TK (Renilla) as a transfection efficacy control (29). Cells were transfected for 6 hours with 2 µl Lipofectamine LTX (Invitrogen) in serum- and antibiotic free OptiMEM according to
manufacturer’s instructions and lysed the next day using the recommended protocol of
the Dual-Luciferase Reporter Assay (Promega).

**Western blotting**

Cells were lysed in 50 µl buffer H (10 mM HEPES, pH 7.9, 50 mM NaCl, 500 mM
sucrose, 0.1 mM EDTA and 0.5%, (v/v) Triton X-100, 1 mM PMSF, 1X Complete™ protease
inhibitor cocktail (Roche Applied Science, Mannheim, Germany) supplemented with
phosphatase inhibitors (10 mM tetrasodium pyrophosphate, 17.5 mM β-glycerophosphate,
and 100 mM NaF; (46, 47)). Samples were run on a 10% SDS-PAGE gel and transferred
onto a nitrocellulose membrane. After blocking with PBS/0.05% Tween-20 (v/v)/5% skim-
milk (w/v), the membrane was incubated with the primary antibody (1:1000) in TBS/0.05%
Tween-20 (v/v)/5% BSA (w/v) overnight at 4°C. The HRP-labeled antibody was incubated
for 1 hour in blocking buffer and developed with ECL (ThermoScientific).

**Quantitative RT-PCR**

Total RNA was isolated and normalised mRNA levels were calculated using
*RPL13A* and *ATP5B* as housekeeping genes (48). Primers used are described in Table S2. IQ
SYBRGreen supermix (Bio-rad, Hercules, CA, USA) was used for amplification of the cDNA.

**ADAM17 activity and binding assay**

ADAM17 activity assay was performed as described earlier (49). In brief, 1 nM
purified recombinant ADAM17 was incubated with or without 0-30 µM purified plasma
M α₁-antitrypsin and assayed for ADAM17 activity using the fluorogenic substrate
MOCAc-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH₂ (R&D systems). Purified plasma M α₁-
antitrypsin (0.5 µg) was incubated for 1 hour at 37°C in a 1:1 molar ratio with ADAM17, ran
on a Native Page Bis Tris (3 – 12% w/v; Invitrogen) gel and visualised by Silver stain. Both
ADAM17 and purified plasma M α₁-antitrypsin were incubated in 50 mM Tris-HCl (pH 7.4),
100 mM NaCl, 10 mM CaCl.
**Statistical analysis**

Results from primary bronchial epithelial cells are expressed as single patients (each dot is the average of one patient in duplicate). Results from Tet-On A549 are shown as mean ± SEM. Data were analysed using two-way repeated-measures analysis of variance (ANOVA) or Student t-test as appropriate. Differences with p-values < 0.05 were considered to be statistically significant.

**Acknowledgements**

The authors would like to thank Marianne van Sterkenburg for her help in setting up the epithelial cell cultures from bronchial biopsies. EFAvtW is an European Alpha-1-Antitrypsin Laurell's Training Awardee (sponsored by Grifols). JAD is a MRC Clinical Training Fellow and recipient of a Sackler Studentship. IH is funded by GlaxoSmithKline. SJM is a Medical Research Council (UK) Senior Clinical Fellow. HK and GM are subsidised by Cancer Research UK. This work was further supported by the Medical Research Council UK (G1002610), the Netherlands Asthma Foundation (3.2.08.032) and the Medical Research Council (UK) and NIHR UCLH Biomedical Research Centre.
References

1. Cichy J, et al. (1997) Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. *J Biol Chem* 272(13):8250-8255.

2. Knoell DL, et al. (1998) Alpha 1-antitrypsin and protease complexation is induced by lipopolysaccharide, interleukin-1beta, and tumor necrosis factor-alpha in monocytes. *Am J Respir Crit Care Med* 157(1):246-255.

3. Subramaniyam D, et al. (2008) TNF-alpha-induced self expression in human lung endothelial cells is inhibited by native and oxidized alpha1-antitrypsin. *Int J Biochem Cell Biol* 40(2):258-271.

4. Bergin DA, et al. (2010) alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. *J Clin Invest* 120(12):4236-4250.

5. Lockett AD, et al. (2013) Alpha-1 Antitrypsin Modulates Lung Endothelial Cell Inflammatory Responses to TNFalpha. *Am J Respir Cell Mol Biol* 49(1):143-150.

6. Janciauskiene S, et al. (2004) Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. *Biochem Biophys Res Commun* 321(3):592-600.

7. Nita IM, et al. (2007) alpha1-Antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. *Int J Biochem Cell Biol* 39(6):1165-1176.

8. Lomas DA, et al. (1992) The mechanism of Z alpha 1-antitrypsin accumulation in the liver. *Nature* 357(6379):605-607.

9. Ekeowa UI, et al. (2010) Defining the mechanism of polymerization in the serpinopathies. *Proc Natl Acad Sci U S A* 107(40):17146-17151.

10. Eriksson S (1965) Studies in alpha 1-antitrypsin deficiency. *Acta Med Scand Suppl* 432:1-85.

11. Elliott PR, et al. (1998) Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. *Am J Respir Cell Mol Biol* 18(5):670-674.

12. Mahadeva R, et al. (2005) Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. *Am J Pathol* 166(2):377-386.

13. Alam S, et al. (2011) Oxidation of Z alpha1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. *Am J Respir Cell Mol Biol* 45(2):261-269.

14. Mulgrew AT, et al. (2004) Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemotactant. *Chest* 125(5):1952-1957.
15. Gooptu B, et al. (2008) Polymers and inflammation: disease mechanisms of the serpinopathies. *J Exp Med* 205(7):1529-1534.

16. Marciniak SJ, et al. (2006) Endoplasmic reticulum stress signaling in disease. *Physiol Rev* 86(4):1133-1149.

17. Yoshida H, et al. (2000) ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response. *Mol Cell Biol* 20(18):6755-6767.

18. Yoshida H, et al. (2001) XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. *Cell* 107(7):881-891.

19. Kroeger H, et al. (2009) Endoplasmic reticulum-associated degradation (ERAD) and autophagy cooperate to degrade polymerogenic mutant serpins. *J Biol Chem* 284(34):22793-22802.

20. Lawless MW, et al. (2004) Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. *J Immunol* 172(9):5722-5726.

21. Hidvegi T, et al. (2005) Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. *J Biol Chem* 280(47):39002-39015.

22. Ordonez A, et al. (2013) Endoplasmic reticulum polymers impair luminal protein mobility and sensitize to cellular stress in alpha1 -antitrypsin deficiency. *Hepatology* 57(5):2049-2060.

23. Siebenlist U, et al. (1994) Structure, regulation and function of NF-kappa B. *Annu Rev Cell Biol* 10:405-455.

24. Schulze-Osthoff K, et al. (1997) Regulation of NF-kappa B activation by MAP kinase cascades. *Immunobiology* 198(1-3):35-49.

25. Vermeulen L, et al. (2003) Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). *EMBO J* 22(6):1313-1324.

26. Singh AB, et al. (2005) Autocrine, paracrine and juxtacrine signaling by EGFR ligands. *Cell Signal* 17(10):1183-1193.

27. Ohtsu H, et al. (2006) ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. *Am J Physiol Cell Physiol* 291(1):C1-10.

28. Luppi F, et al. (2007) Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through
epidermal growth factor receptor transactivation. Lung Cancer 56(1):25-33.

29. Davies MJ, et al. (2009) Neuroserpin polymers activate NF-kappaB by a calcium signaling pathway that is independent of the unfolded protein response. J Biol Chem 284(27):18202-18209.

30. Greene CM, et al. (2010) Anti-apoptotic effects of Z alpha1-antitrypsin in human bronchial epithelial cells. Eur Respir J 35(5):1155-1163.

31. Richards CD, et al. (1996) Oncostatin M inhibits IL-1-induced expression of IL-8 and granulocyte-macrophage colony-stimulating factor by synovial and lung fibroblasts. J Immunol 156(1):343-349.

32. Miranda E, et al. (2010) A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency. Hepatology 52(3):1078-1088.

33. Tape CJ, et al. (2011) Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A 108(14):5578-5583.

34. Richards FM, et al. (2012) Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One 7(7):e40597.

35. Le Gall SM, et al. (2010) ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 123(Pt 22):3913-3922.

36. Lomas DA (2013) Twenty years of polymers: a personal perspective on alpha-1 antitrypsin deficiency. COPD 10 Suppl 1:17-25.

37. Beswick EJ, et al. (2008) Macrophage migration inhibitory factor and interleukin-8 produced by gastric epithelial cells during Helicobacter pylori exposure induce expression and activation of the epidermal growth factor receptor. Infect Immun 76(7):3233-3240.

38. De Boer WI (2002) Cytokines and therapy in COPD: a promising combination? Chest 121(S Suppl):209S-218S.

39. Farkas L, et al. (2005) Expression of CXC chemokine receptors 1 and 2 in human bronchial epithelial cells. Chest 128(5):3724-3734.

40. Keates S, et al. (2007) Macrophage-inflammatory protein-3alpha mediates epidermal growth factor receptor transactivation and ERK1/2 MAPK signaling in Caco-2 colonic epithelial cells via metalloproteinase-dependent release of amphiregulin. J Immunol 178(12):8013-8021.

41. Kim S, et al. (2011) CCL20/CCR6 feedback exaggerates epidermal growth factor receptor-dependent MUC5AC mucin production in human airway epithelial (NCI-H292) cells. J Immunol 186(6):3392-3400.
42. Irving JA, et al. (2011) The serpinopathies studying serpin polymerization in vivo. Methods Enzymol 501:421-466.

43. van Wetering S, et al. (2000) Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J Investig Med 48(5):359-366.

44. van Wetering S, et al. (2007) Epithelial differentiation is a determinant in the production of eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4 and IL-13. Mol Immunol 44(5):803-811.

45. Snapp EL, et al. (2006) Monitoring chaperone engagement of substrates in the endoplasmic reticulum of live cells. Proc Natl Acad Sci U S A 103(17):6536-6541.

46. Harding HP, et al. (2000) Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6(5):1099-1108.

47. Novoa I, et al. (2001) Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol 153(5):1011-1022.

48. van Schadewijk A, et al. (2012) A quantitative method for detection of spliced X-box binding protein-1 (XBP1) mRNA as a measure of endoplasmic reticulum (ER) stress. Cell Stress Chaperones 17(2):275-279.

49. Willems SH, et al. (2010) Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J 428(3):439-450.

50. Scott DW, et al. (2005) Increased GADD gene expression in human colon epithelial cells exposed to deoxycholate. J Cell Physiol 202(1):295-303.

51. van ‘t Wout EF, et al. (2012) alpha1-antitrypsin production by proinflammatory and antiinflammatory macrophages and dendritic cells. Am J Respir Cell Mol Biol 46(5):607-613.
**Supplementary data**

![Graph showing NF-κB luciferase activity](image)

**Figure S1.** Tet-On A549 cells overexpressing Z α1-antitrypsin show enhanced NF-κB signalling upon an inflammatory stimulus.

Cells were treated as in Figure 1C, only cells were induced with doxycycline (dox) instead of OSM (mean ± SEM, n=3).

![Graph showing FRAP](image)

**Figure S2.** Z α1-antitrypsin does not alter ER protein mobility.

Primary bronchial epithelial cells were transiently transfected with ER-GFP and fluorescence recovery was measured by fluorescence recovery after photo-bleaching (FRAP). Recovery is displayed relative to pre-bleach fluorescence intensity (mean ± SEM, n=9-10).
Figure S3. Critical concentration for polymer formation within cells.

A. Dose-response doxycycline on a CHO stable cell line overexpressing Z α1-antitrypsin under the control of a Tet-On responsive promoter. Intracellular total and polymeric Z α1-antitrypsin levels are measured by ELISA. B. Z α1-antitrypsin-expressing A549 cells induced with doxycycline and stimulated in the presence of lactacystin. Intracellular total and polymeric Z α1-antitrypsin levels are measured by ELISA.
Figure S4. Increased NF-κB response in ZZ primary bronchial epithelial cells is caused by increased phosphorylated ERK.

A. Representative western blots of the activation of the NF-κB proteins IKKβ and NF-κB p65 and degradation of total IκBα of whole cell lysates from undifferentiated primary bronchial epithelial cells knocked-down for α1-antitrypsin by siRNA (see Figure 3A). Densitometry was done on four independent experiments in duplicate (mean, n=3). B. Densitometry of the Western blots shown in Figure 3A (mean, n=3-4).
Figure S5. Overexpression of Z α₁-antitrypsin downregulates ERK1/2 phosphorylation.

A. Alpha1-antitrypsin (AAT) production after transfection of HeLa cells with pcDNA3.1 containing M or Z α₁-antitrypsin (or empty vector as control). B. Representative western blot of phospho ERK1/2 in HeLa cells after transfection with M or Z α₁-antitrypsin. High amounts of Z α₁-antitrypsin are able to inhibit phospho ERK1/2 at the same rate as M α₁-antitrypsin does.
Figure S6. Increased ERK1/2 phosphorylation in ZZ cells does not enhance proliferation.

A. Cells were seeded at 3 \times 10^4 cells/well and cultured for 48 hours as indicated. Starvation medium is full medium except BSA and the SingleQuot supplements EGF and BPE to minimise the effects of exogenous growth factors. FR180204, a specific ERK inhibitor did not change proliferation rates. U0126, a specific MEK inhibitor, was toxic to both MM and ZZ cells. B. ZZ cells were seeded at 3 \times 10^4 cells/well and cultured for 48 hours in the presence of 1 mg/ml M α1-antitrypsin.
The ERK pathway in α1-antitrypsin deficiency

Figure S8. Confirmation of α1-antitrypsin knock-down by siRNA in primary bronchial epithelial cells.

A. SERPINA1 mRNA knock-down was >90% efficient (left panel) and after α1-antitrypsin up-regulation with OSM mix >98% efficient (right panel). Neuroserpin (NS) siRNA served as a control (mean, n=3). B. α1-antitrypsin was undetectable in cell supernatant after knock-down of α1-antitrypsin, measured by ELISA (mean, n=3).

Figure S7. ZZ cells do not display increased phosphorylation of ADAM17.

ZZ primary bronchial epithelial cells were treated for 24 hours with 1 mg/ml purified plasma M α1-antitrypsin. Representative western blot of phosphorylated ADAM17 (Thr735) (n=3).
### Table S1. Patient characteristics.

|                          | PiMM controls | PIZZ patients |
|--------------------------|---------------|---------------|
| age (mean, range)        | 61 (51-83)    | 52 (43-57)    |
| sex (M/F)                | 3/3           | 3/3           |
| GOLD-stage (0/I/II/III)  | 2/2/1/1       | 3/1/1/1       |
| smoking status (current/never/ex) | 2/0/4   | 0/1/5         |

### Table S2. qPCR primers.

| Name   | Forward primer / Reverse primer | Melting temp. (°C) | Ref. |
|---------|---------------------------------|--------------------|------|
| AREG    | 5’GGTTGGTTGCTGCTGCTTTG 3’       | 62                 | -    |
|         | 5’AGGTGCTATTGAGGTCAAATCC 3’     |                    |      |
| CHOP    | 5’GCACCCTCCAGAGCCCTACTCTCC 3’   | 62                 | (48) |
|         | 5’GCACCTCCAAGCTTTCCCCCTGCG 3’   |                    |      |
| EGF     | 5’TGCAGAGGGGATACGCCCTAA 3’      | 62                 | -    |
|         | 5’CAAGAGTACAGGCAATTTCCCAAA 3’   |                    |      |
| GADD34  | 5’ATGTATGGTGAGCGAGGCG 3’        | 62                 | (50) |
|         | 5’GCAGTGTCCTTATACGAGAGGC 3’     |                    |      |
| HB-EGF  | 5’TGGACCTTTTGAGTCTACTCTTATCC 3’ | 62                 | -    |
|         | 5’CGTGCTCCCTTTGTGTGCGTG 3’      |                    |      |
| IL8     | 5’CTGGACCCCAAGGAAAAC 3’         | 60                 | -    |
|         | 5’TGGCAACCCCTCACAGCAAGAC 3’     |                    |      |
| SERPINA1| 5’AAGGCAAATGGGAGAGGACC 3’       | 60                 | (51) |
|         | 5’AAGAAGATGGCGGGTGCCAT 3        |                    |      |
| TGFα    | 5’AGGTCCGAAAAACTGTGAGT 3’       | 62                 | -    |
|         | 5’AGCAAGCGGTCTCTCCTCCCTC 3’     |                    |      |
| XBP1spl | 5’TGCTGAGTCCGCAGCAGGTG 3’       | 62                 | (48) |
|         | 5’GCTGGGAGGGCTCTGCGGGAAG 3’     |                    |      |
The ERK pathway in α1-antitrypsin deficiency
